Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | DRD1 | P21728 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | DRD5 | P21918 | 5/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027382 | 0.87 | MAOA (0.60) | MAOADRD1DRD2DRD4DRD5 | |
| SCHEMBL5518952 | 0.83 | DRD1 (0.51) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL9433750 | 0.80 | DRD1 (0.48) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL9259446 | 0.79 | DRD1 (0.64) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL27156813 | 0.79 | DRD1 (0.50) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL9261882 | 0.79 | DRD1 (0.51) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL19439323 | 0.79 | DRD1 (0.47) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL26668032 | 0.78 | KMT2A (0.55) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL9259474 | 0.77 | DRD1 (0.61) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL28742343 | 0.77 | CA1 (0.68) | DRD1DRD2DRD4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| CN-114853730-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| CN-114853730-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-114315796-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-04-12 | — | — | CN | disclosed |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | MAOA 4020/4885DRD1 3867/4885DRD2 3469/4885 |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | STK16, STK4, STK26 | MAOA 4658/4885DRD1 3255/4885DRD2 3999/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MAOA 2176/4885DRD1 4840/4885DRD2 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.